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 Impaired endothelial function and microvascular dysfunction are frequently observed in 
individuals with cardiovascular risk factors such as obesity, insulin resistance, and type 2 
diabetes. Reduced nitric oxide (NO) bioavailability is considered to be central to the 
development of these risk factors. NO can be generated via enzymatic reaction via NO synthase 
which requires the amino acid arginine. Evidence suggests that the amino acid citrulline is more 
effective at increasing circulating arginine levels than arginine supplementation alone. The 
purpose of this pilot study is to determine the potential for citrulline-rich watermelon juice 
(WMJ) to attenuate the reduction in postprandial endothelial function associated with reduced 
skeletal muscle microvascular blood flow (MVBF) during hyperglycemia.  Seventeen (12 
female) non-obese (%Fat Mass= 27.72±7.89%) young adults (Age= 23±3y), with normal or 
overweight BMI (BMI= 23.48±3.22kg/m2) were enrolled in this study.  In a randomized, 
crossover, double-blinded design, participants supplemented with WMJ or placebo (PLA) 
(average 12.8, 10-16 days) then underwent an oral glucose tolerance test (OGTT) after an 
overnight fast. Flow-mediated dilation (FMD) was greater after WMJ compared to PLA 
following the oral glucose challenge (treatment p=0.038).  Baseline oxygen saturation (StO2) 
was significantly higher in WMJ vs PLA (p=0.031) and the baseline StO2 area under the curve 
(AUC) was significantly greater in WMJ vs PLA (p=0.03).  Our findings suggest that WMJ 
supplementation is a potentially effective method for improving vascular responsiveness during 





Chapter 1. Literature Review 
1.1 Introduction 
17.9 million people die each year from cardiovascular disease (CVD) which accounts for 
31% of deaths worldwide with the majority of these coming from a heart attack and stroke [20].  
Cardiovascular disorders are related to the heart and vessels and include coronary heart disease 
and rheumatic heart disease.  Individuals with CVD have a higher likelihood of other risk factors 
such as endothelial dysfunction, hypertension, atherosclerosis, insulin resistance, obesity, and 
type 2 diabetes (T2D).  These diseases and risk factors have strong vascular and endothelial 
components if improved could improve quality of life and reduce the frequency of premature 
death.  CVD and many of the related diseases are known or suspected to be related to diminished 
arginine and nitric oxide (NO) bioavailability which contribute to vascular and endothelial 
dysfunction [33]. 
 The vascular and endothelial systems work in conjunction as a network of vessels and 
muscles throughout the entire body.  The vascular system is responsible for distributing blood 
and nutrients throughout the body to all of the tissues.  The endothelium acts as a regulator as 
well as a barrier between the blood and other tissues of the body.  Blood flow is largely affected 
by the vascular tone which can be vasodilated or vasoconstricted to change the amount of blood 
flow to an area. Vascular tone is altered by endothelium-derived or non-endothelium derived 
vasodilation or vasoconstriction.   
Non-endothelium dependent changes in vascular tone are regulated by the autonomic 
nervous system.  Individuals’ sympathetic response to extrinsic stimuli such as stress, danger, or 
pain directly elevating vascular resistance [39].  The endothelium is innervated with neural 
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transmitters from the autonomic nervous system signals the change in vascular tone.  
Neurotransmitters including norepinephrine and acetylcholine can act on the endothelium and 
counteract endothelial-dependent changes in the vasculature.  Norepinephrine when bound to the 
α2-adrenergic receptors on the endothelium counteract the endothelium-dependent vasodilation 
and induce vasoconstriction of the endothelium smooth muscle cells [39].  Acetylcholine can 
mediate vasorelaxation by regulating NO release, but it can also inhibit NO production if 
activated on the M2 and M3 receptors [39].  Conversely, endothelium-dependent changes are 
mediated by the bioavailability of NO.  
 Diminished NO bioavailability is considered to play a role in nearly all cardiometabolic 
disease states.  Patients with T2DM are at increased risk for developing mico- and macrovascular 
dysfunction which contributes to the increased risk of CVD in this group.  This review will focus 
on the effects of hyperglycemia on vascular and endothelial function as well as a possible 
solution by increasing the bioavailability of NO.  Citrulline has shown promising effects on NO 
bioavailability that could dampen the effects of cardiometabolic disease on the vascular and 
endothelial systems. 
1.2 Nitric Oxide 
Discovered in 1987, NO is a vasoprotective molecule that is synthesized by endothelial 
nitric oxide synthase (eNOS) which can be a major component to fighting cardiovascular disease 
[21].  NO is responsible for changing the tone of the vasculature regulating hemodynamics of the 
associated tissues.  Endothelium-derived NO is synthesized from the amino acid L-arginine by 
eNOS, yielding L-citrulline as a byproduct [2].  After NO is synthesized, NO diffuses across the 
endothelial cell membrane, entering the vascular muscle cells where soluble guanylate cyclase 
(sGC) is activated leading to an increase in cyclic guanosine monophosphate (cGMP) synthesis 
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[4].  cGMP acts as a secondary messenger that controls the vascular tone and platelet function by 
mediating the effects of NO [4].  This process makes NO a potent vasodilator while also 
suppressing platelet aggregation, leukocyte migration and cellular adhesion to the endothelium, 
and attenuates vascular smooth muscle cell proliferation and migration [22]. 
Nitric oxide undergoes rapid oxidation to form nitrite, and further oxidation into nitrate. 
Conversely, NO can be generated the reduction of nitrate and nitrite by a series of biological 
reactions in the body (25, 26).  This reaction along with oral ingestion are the two main sources 
of nitrate/nitrites in human metabolism [24].  Once ingested, foods naturally high in nitrates such 
as beetroot, spinach, and celery are broken down by the saliva and reduced from nitrate to nitrite 
and are absorbed through the gastrointestinal tract entering circulation [23].  Nitrite is then 
reduced to NO in the cells and tissues by several proteins and enzymes [24].  Carlstrom et al 
(2015) suggests that higher chronic doses of nitrates could be detrimental to endothelial function 
by increasing the formation of reactive nitrogen oxides as well as decreasing the amount of sGC 
while smaller and acute doses are beneficial [23].   
1.3 Citrulline 
Citrulline is a non-essential amino acid that has been shown to increase the 
bioavailability of NO production by increasing the bioavailability of arginine, a precursor to NO. 
Citrulline is also an important component in the urea cycle in the liver and kidneys [6].  While 
being mainly used in NO production, citrulline has been used as a biomarker for functional small 
bowel enterocyte mass due to being almost exclusively synthesized in the small intestine [31]. In 
addition, increased plasma citrulline has been noted as a potential marker for renal function due 
to the kidneys being the main site of citrulline conversion to arginine [32].  Citrulline is typically 
supplemented by watermelon juice, watermelon extract, pharmaceutical grade citrulline, or 
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citrulline conjugated with malate (1:1 ratio) [30].  The main food source of citrulline is 
watermelon, particularly the rind and seeds have the highest concentrations, with 1.6-3.5 g/kg of 
citrulline per whole watermelon [1].  Citrulline is effective at doses as low as 1g/day and as high 
as 10g/day with no known toxicity [1, 50].  With the possible endothelial benefits, watermelon 
products (juice, extract, etc.) should be considered as a natural, relatively cost-effective 
alternative to pharmaceutical-grade citrulline. 
The oxidative production of NO and citrulline requires the three main nitric oxide 
synthase enzymes (eNOS, iNOS, and nNOS) [6].  Arginine is hydrolyzed yielding NO and 
citrulline.  Citrulline is then sustained in the endothelial cells yielding more arginine to create 
NO [7].  Citrulline is coproduced with NO as an end product of NOS activity, which can be then 
be recycled into arginine for additional NO production in this citrulline- NO cycle [16].  When 
ingested, approximately 40% of arginine is catabolized by intestinal bacteria then passes through 
the liver where arginase breaks down arginine yielding urea and ornithine accounting for another 
10-15% extraction [3, 15].  Unlike arginine, citrulline is not acted on by first-pass extraction in 
the liver by arginase enzyme allowing for citrulline to be converted to argininosuccinate and 
subsequently arginine in the kidneys by argininosuccinate lyase [55].  This process yields more 
circulating arginine allowing eNOS to produce NO.   
NO is an integral part of endothelial physiology, leading to increased vasodilation, 
therefore improving blood pressure and serum cholesterol along with several other factors.  
Citrulline can be converted to arginine in the kidneys, bypassing the uptake of the liver allowing 
for an increase in NO downstream.  Conversely, ingested arginine will be taken up by the liver, 
and converted into urea and ornithine, thereby diminishing the amount of arginine that can be 
used to create NO.   
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1.4 Vasoprotective effects 
Individuals with diabetes, impaired glucose tolerance, and even normal individuals post 
glucose intake suffer from impaired endothelium-dependent NO mediated vasorelaxation [11].  
Endothelial dysfunction has been shown to possibly be linked with low levels of arginine as well 
as a possible increased production of oxygen-derived free radicals that are likely associated with 
repeated or prolonged bouts of postprandial hyperglycemia [10].  Kwano et al. (1999) found a 
decreased association in brachial artery vasodilation with increased plasma levels of 
thiobarbituric acid reactive substances (TBARS) that parallel the plasms glucose levels in the 
respective groups, while serum nitrite/nitrate levels remained the same post glucose loading [10].  
Diseases that cause impaired endothelial function and increase reactive oxygen species (ROS) 
such as atherosclerosis and diabetes, have been shown to cause eNOS uncoupling, which causes 
eNOS to produce the oxygen-derived free radical superoxide instead of NO which lead to a 
reduction in eNOS activity [27, 21].  During periods of high oxidative stress, superoxide is 
produced.  Superoxide then reacts with NO to produce peroxynitrite.  The production of 
peroxynitrite leads to the oxidation of tetrahydrobiopterin (BH4) into BH2 which cannot be 
recycled back into BH4, causing the uncoupling of eNOS and reducing oxygen to superoxide and 
diminishing the synthesis of NO [28].  In healthy individuals, BH4 maintains the function of 
eNOS by being oxidized into trihydropterin radicals (BH3H
+) which are then recycled into BH4 
by reduction [28]. 
1.5 Flow-Mediated Dilation and Near-Infrared Spectroscopy 
 Changes in the vascular and endothelial tissues are best measured by using flow-mediated 
dilation (FMD) of the brachial artery.  Near-infrared spectroscopy (NIRS) is another method to 
measure microvascular responses post-ischemia and can be used in conjunction with FMD.  
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FMD and NIRS have been used in conjunction to measure the vascular and microvascular 
response to hyperglycemia.  FMD is a non-invasive measure believed to reflect endothelium-
dependent NO-mediated arterial function and vascular health [41].  NIRS has been proven to be 
a valid measure to detect changes in oxidative metabolism as well as microvascular 
responsiveness during an oral glucose challenge [42, 43].  FMD and NIRS have recently been 
used in conjunction to support the relationship of down (brachial artery FMD) and upstream 
(forearm NIRS) vascular reactivity [44, 45, 46].  Soares et al. (2019) showed a significant 
correlation (r=0.66; P = 0.001) between the NIRS reperfusion slope and FMD % in healthy 
active individuals [44].   
1.6 Type 2 Diabetes 
 T2D involves many complications with the vascular and endothelial systems.  Vascular 
disease, which originates from endothelial dysfunction, is the primary cause of morbidity and 
mortality in individuals with T2D [34, 35, 36].  Insulin-stimulated NO production via increasing 
NOS stimulation, thus insulin-resistant individuals have a reduced NO-mediated vasodilatory 
response [48].  Individuals with T2D have diminished endothelium-derived vasodilatory in 
response to NO as well as impairments to the sympathetic nervous system compounding further 
vascular dysfunction [48].  Endothelial dysfunction is likely due to chronic hyperglycemia, the 
eNOS inhibitor asymmetric dimethylarginine  (ADMA), and ROS in individuals with T2D.  
Chronically elevated glucose levels can inactivate the NOS cofactors located in the kidney and 
endothelium, causing NOS uncoupling and therefore reductions in citrulline concentrations [37, 
38].  Individuals with T2D typically have elevated circulating free fatty acid levels.  The elevated 
levels of free fatty acids activate lipoprotein lipase to metabolize the high levels of free fatty 
acids circulating and decrease insulin sensitivity.  The elevated levels of circulating free fatty 
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acids could be a contributing factor to reduced NOS activity thus a decreased NO bioavailability 
in insulin-resistant individuals [48].    
1.7 Hyperglycemia 
 Postprandial hyperglycemia in which the vascular recovery of the endothelium is 
compromised after ingesting glucose or a mixed meal has been shown to contribute to CVD.  
Recent evidence demonstrates that acute or postprandial hyperglycemia shows impairments in 
vascular function of individuals with a history of vascular endothelial dysfunction as well as 
healthy individuals [8, 9, 10, 29].  The severity of postprandial hyperglycemia has been shown to 
be a better predictor of future CVD mortality compared with fasting glucose in both diabetic and 
normal individuals [8].  Numerous other studies have observed a graded relationship between 
increasing fasting or postprandial glucose levels and the risk of cardiovascular events in 
nondiabetic populations [9].  Kawano et al. (1999) showed that glucose loading suppresses 
endothelium-dependent vasodilation in healthy individuals as well as impaired glucose tolerance 
groups, measured by FMD [10].  This decrease in FMD could be due to decreases in NO 
synthesis, increased uncoupling of eNOS, and/or greater consumption of NO by reactive oxygen 
species [10].  Oxidative stress induced by hyperglycemia decreases the activity of 
dimethylarginine dimethylaminohydrolase (DDHA) which degrades ADMA, whose role is to 
inhibit eNOS (19).  Higher levels of ADMA relative to arginine have been related to an 
increased CVD risk by decreasing the biosynthesis of NO due to inhibiting the binding of 
arginine to eNOS (19).  Acute hyperglycemia induces lipid peroxidation and increases ADMA: 
arginine independent of any changes in inflammation leading to the suppressed vascular function 
(18).   
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Endothelial dysfunction has been linked to individuals with diabetes as well as 
individuals with chronic hyperglycemia which are often seen as the cause of endothelial function 
[10].  These diseases contribute to abnormalities in the vascular and smooth muscle cells 
contributing to vascular disease.  Since eNOS is constitutively active, the bioavailability of NO is 
considered a marker of vascular health.  The uncoupling of eNOS is thought to be a major 
contributor to the endothelial dysfunction associated with aging, cardiometabolic disease, and 
menopause. The bioavailability of NO is a reflection of the balance between its production from 
NOS and its degradation, particularly by the ROS superoxide [11].   
NADPH oxidases transfer electrons across biological membranes, with oxygen often 
being the acceptor of the electron [47].  The free radical superoxide has been shown to react with 
NO to produce peroxynitrite which decreases NO bioavailability [21].  NO and superoxide have 
opposite effects on the vasculature.  NADPH-dependent ROS generation causes the depletion of 
NO and promotes the uncoupling of NOS [47].  This NOX activation leads to an increased 
production of superoxide leading to a breakdown of NO [47].  Notably, this relationship between 
NO and NADPH derived superoxide act as a reversible signaling mechanism [47].  Furthermore, 
superoxide can be removed by superoxide dismutase to reduce the breakdown of NO [49]. 
Citrulline has been shown to increase levels of arginine, nitrate/nitrite (NOx), and cGMP 
activities after citrulline supplementation in healthy young adults [3, 12].  While other studies 
have seen similar increases in arginine availability and increased urinary NOx levels, endothelial 
function is measured by brachial artery FMD, but acute supplementation with citrulline (~7 days) 
did not show an increase in FMD [3, 13].   
Acute (~7 days) citrulline supplementation has shown an increase in exercise 
performance and prolongs time to fatigue in mice [17].  In humans, acute ingestion (6g/day for 
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14 days) of citrulline has shown a significant increase to blood flow and plasma arginine levels 
in older men and women despite not showing an increase in NOx during exercise [14].  Other 
studies have shown an increase in endurance exercise performance with citrulline 
supplementation, including an increase in plasma nitrate-nitrite for both the citrulline (21%) and 
arginine (28%) groups.  This increase in plasma nitrate-nitrite in both groups, despite the 
significantly improved tissue oxygen index and power outputs for the citrulline group, put into 
question to what extent does plasma nitrate-nitrite reflect skeletal muscle NOS activity (12). 
To summarize, vascular and endothelial function plays a pivotal role in the health and 
wellbeing of individuals with NO and its bioavailability at the foundation.  There is strong 
evidence that oral consumption of watermelon juice could be beneficial in attenuating the 
decrement seen in endothelial function during hyperglycemia.   
1.8 Purpose  
The purpose of this pilot study is to determine the potential for citrulline-rich watermelon 
juice to attenuate the reduction in postprandial endothelial function associated with reduced 
skeletal muscle microvascular blood flow (MVBF) during hyperglycemia.  We hypothesize that 
the watermelon juice supplementation will attenuate the reduction in endothelial dysfunction and 
microvascular blood flow during an oral glucose challenge.  We also hypothesize that 
watermelon juice will increase L-arginine bioavailability during hyperglycemia and correlate 






Chapter 2. Methods 
2.1 Participants  
 Seventeen participants (5 Male, 12 Females) were recruited through word of mouth and 
flyers from the LSU campus.   Participants were healthy males and females 18 – 40 years of age 
with a BMI between 18-29.9 kg/m2.  Participants were excluded if they or a first-degree relative 
had type 1 or 2 diabetes, were an active smoker, allergic to watermelon, have a history of 
vascular disorders, on any known medication that could influence the study outcomes, or taking 
supplements including arginine, citrulline, or beta-alanine.   
 Participants interested in participation filled out a health screening, PAR-Q, as well as the 
informed consent for the study.  After these documents were reviewed, if particpants met all of 
the inclusion/exclusion criteria, they were scheduled for a screening visit then a follow-up OGTT 
visit.  The study was a double blinded, randomized, counterbalanced design.  
2.2 Screening Visit 
 During the screening visit, participants were required to come in fasted from food and 
drink (except water) for at least 10 hours, 48-72 hours without alcohol or strenuous exercise.  A 
fasting baseline blood draw was taken to measure glucose, lipids, and CBC.  Then participants 
had body composition measured by dual x-ray absorptiometry (DXA).  Women were required to 
take a pregnancy test before the DXA.  Participants were briefed on the risks of the DXA, then 
prepared by removing all metal and shoes for the full-body scan.  Once the DXA was completed 
the participants were randomized and put into contact with the distributor at the LSU AG Center 
to schedule out their visits for receiving the supplement or placebo.   
2.3 Supplement Visits 
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 Participants were required to have a minimum of 10 and a maximum of 17 doses of 
supplementation (average 12.8, 10-16 days).  The participants were asked to receive the juice or 
placebo from the food science laboratory at LSU Agricultural Center where they would take one 
dose per day.  On weekends participants were provided with two doses of juice or placebo to 
account for the closure of the AG Center.  Participants were also provided with juice or placebo 
for anticipated instances where they could not make it to the AG Center.  Both the participants as 
well as the researchers administering the OGTT were blinded to the supplementation.   
2.4 Washout Period 
Before starting phase 2 of supplementation, the participants were required to wash out a 
minimum of 14 days following the day of the OGTT.  Immediately before the initiation of phase 
2, participants underwent a post-washout fasted blood draw.  Following the blood draw, the 
participant would be again put into contact with the AG Center and start receiving the condition 
they did not receive prior.   
2.5 Visit 2 & 3: Oral Glucose Tolerance Test – Postprandial FMD and MVBF 
 Participants arrived in the morning fasted from food and drink (except water) for at least 
10 hours, 48-72 hours without alcohol or strenuous exercise.  Body composition was measured 
by DXA and pregnancy test was administered for females before testing.  Next, participants 
rested for 30 minutes in the supine position while wearing a heart rate monitor (Zephyr, 
Bioharness) to measure heart rate and heart rate variability.  Resting metabolic rate was 
measured via indirect calorimetry for 20 minutes. MVBF (near-infrared spectroscopy) was 
measured for 3 rounds of 10 seconds on 2 minutes off then brachial artery FMD (ultrasound) was 
taken following a 5-minute occlusion.  An intravenous catheter was inserted in the patient's left 
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arm and a baseline blood sample was taken.  The participant then had 5 minutes to drink the 75-
gram glucose solution, once the participant was finished, a timer was started.  Blood was drawn 
from the IV at 15, 30, 60, 90, and 120 minutes post glucose ingestion.  Postprandial 
measurements of FMD and MVBF were taken at 30, 60, and 90 minutes post glucose ingestion. 
2.6 Flow-Mediated Dilation 
 FMD measurements were taken according to the standard procedures supported by the 
American Heart Association [40].  With permission from the participant, A blood pressure cuff 
(Delphi) was placed on the upper forearm distal to the ultrasound probe and proximal to the 
NIRS optodes.  The participant was asked to stay still through the duration of the measurement 
with their right arm out at 80 degrees and supinated.  The brachial artery of the right arm was 
identified using color and Doppler modes and scanned using B-mode on the ultrasound 
(Hologic).  Following at least 2 minutes post microvascular occlusion, baseline images were 
recorded of the brachial artery pre-occlusion.  Each image attained was ~17 seconds in duration.  
The ultrasound probe was held in place by using an ultrasound adjustable clamp (QUIPU, Italy) 
to ensure image quality and reproducibility.  The cuff was inflated using a rapid cuff inflation 
system (Hokanson E20, Bellevue WA) controlled using a custom-built control system Labview 
Software algorithms (developed by Pedro J Chacon Dominguez, Jin-Woo Choi, and Brian A 
Irving).  Inflation was continuous at 250mmHg for 5 minutes.  Before the release of cuff 
inflation, the participant was reminded to remain still and videos of the brachial artery were 
attained immediately post-deflation, 1, 3, and 5 minutes post deflation.  FMD videos were 
analyzed by Brachial Analyzer for research software (mia-llc, Coralville, Iowa).  Then FMD was 
measured using the following equation: 
𝐹𝑀𝐷 = (𝑃𝑒𝑎𝑘 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 – 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟) ÷ 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 
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2.7 Microvascular Blood Flow-Near Infrared Spectroscopy (NIRS) 
 The NIRS system was calibrated prior to the subject arrived for each visit.  The NIRS 
optodes (Oxymon MKIII, Artinis Medical Systems) were placed longitudinally on the flexor 
digitalis superficialis (forearm) and measured to ensure reproducibility.  The optodes were 
secured in place with two-sided adhesive tape and further anchored in place with additional 
medical tape.  The rapid inflation cuff was placed proximal to the optodes.  After ensuring 
correct probe placement the participants laid their supine at 80 degrees and were instructed to 
remain still for the course of the measurements.  The cuff was rapidly inflated to 60mmHg for 10 
seconds and rapidly deflated for 2 minutes for 3 rounds.  NIRS signals for oxygenated 
(O2Hb/O2Mb), deoxygenated (HHb/HMb), total (tHb/tMb) hemoglobin/myoglobin, and tissue 
O2 Saturation (TSI) (%) were continuously monitored through the MVBF as well as FMD. 
The microvascular blood flow response was measured by calculating the slope of the 
linear increase total hemoglobin (tHb): BF= (((DtHb x 60)/ ((([Hb] x1000)/4))x1000/10 in ml-1 
•min•100ml-1. Baseline TSI was calculated from the 2 minutes prior to ischemic occlusion. The 
ischemic-reperfusion slope was calculated from the slope of linear increase at the point of cuff 
release to 10-seconds post-reperfusion.  
 Paired t-test and repeated measures and mixed mold two-way ANOVA were utilized to 
analyze data where appropriate (Prism, Graphpad).  Main effects were defined as “time” 
(between individual time points within a visit) and “treatment” (PLA vs. WMJ).  Multiple 
comparisons were made by Holm-Sidak’s test.  Statistical significance was declared at P<0.05.  
All data were reported as mean ±SEM.  Calculations of the incremental area under the curve 
(AUC) were made by the trapezoidal method.  
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Chapter 3. Results 
3.1 Participant Characteristics  
 All individuals were non-obese (%Fat Mass= 27.72±7.89%), young adults (Age= 23±3y), 
with normal or overweight BMI (BMI= 23.48±3.22kg/m2) with 17 total participants (12 female, 
5 male).  Two of the female participants completed only 1 of the visits and were removed from 
repeated measures analysis.  The participant characteristics did not differ from baseline to their 
last visit as shown in Table 1.  The average time of supplementation for WMJ trial supplemented 
was 13 days (Range 10-15) and the average time for the placebo was 13 days (Range: 10-16).  
The washout period lasted for 16 days (Range: 14-21) days.  Due to technical issues with the 
production of the WMJ supplement, the first 5 participants were given WMJ in the first trial, the 
following 5 participants were given PLA as the first trial to match this, then the remaining 
participants were randomized to the order of their trials.  However, the double-blinded, cross-




3.2 Oral Glucose Tolerance Test 
Participants baseline blood glucose concentrations increased from (5.20±0.37 mmol·L-1) 
at baseline to (6.73±0.93 mmol·L-1) at 15 minutes and peaking at (8.06±1.38 mmol·L-1) at 30 
minutes, then (7.52±2.10 mmol·L-1) at 60 minutes, to (6.10±1.52 mmol·L-1) at 90 and finally 
(5.53±1.60) at 120 minutes post glucose ingestion.  Figure 1 depicts a significant time effect in 
glucose levels (p=<0.0001) with no significant treatment (p=0.18) or treatment by time effect 
(p=0.74) in WMJ or PLA groups.  Glucose AUC was not significant throughout the trail 
(p=0.43).  RER at baseline was 0.787 then 0.841 at 60 minutes and 0.826 at 120 minutes post 




3.3 Flow-Mediated Dilation 
 Table 2 displays the baseline and peak brachial artery diameter at 0 (pre glucose 
ingestion) 30, 60, and 90 minutes following the oral glucose ingestion.  Figure 2b depicts the 
percent change in FMD between WMJ and PLA groups following the oral glucose challenge 
with a significant treatment effect (p=0.038).  Percent change in 60-second post occlusion FMD 
has a time effect trending towards significance (p=0.057) in the WMJ group demonstrated in 
Figure 2a.  A higher percentage of participants demonstrated a longer time to peak artery 








3.4 Near-Infrared Spectroscopy 
 At 30 minutes post glucose ingestion, plasma glucose increases while oxygen saturation 
(StO2) decreases in both WMJ and PLA groups as shown in Figure 4.  Baseline StO2 (average 
StO2 180 seconds prior to cuff occlusion) was significantly higher in WMJ vs PLA (p=0.031) 
and the baseline StO2 area under the curve (AUC) was significantly greater in WMJ vs PLA 
(p=0.03) as depicted in Figure 5.  Hyperglycemia has been cited to reduce microvascular 
endothelial function [54]. Slope 2 (reperfusion slope) is inversely correlated with plasma glucose 
(R2=0.17; p=0.0002) depicted in Figure 6.  Figure 7 displays a significant time effect (p=0.03) 
and time by treatment effect trending towards significance (p=0.072) in WMJ vs PLA 
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reperfusion slope.  Reperfusion AUC (8-minute) shows a significant time effect (p<0.0001) and 
trends towards a significant treatment effect (p=0.13) as displayed in Figure 8a.  The mean 
reperfusion AUC (8-minute) trends towards a significant increase in WMJ vs PLA group 
(p=0.086) as exhibited in Figure 8b.  Figure 9 depicts the microvascular blood flow from 0-
minute (pre-glucose) to 90 minutes post glucose ingestion showing a significant time effect 
(p=0.023) with no significant treatment effect.  No significant differences were observed in mean 
blood flow or baseline blood flow in WMJ vs PLA despite baseline blood flow trending toward 

















Chapter 4. Discussion 
4.1 Hyperglycemia and Vascular Function 
Diseases such as T2D, hypertension, obesity, and CVD all negatively impact health on a 
global scale.  The decrement in quality of life caused by these diseases has been linked to 
diminished vascular-endothelial function.  Hyperglycemia has been shown to cause a reduction 
in blood flow and vascular responsiveness [8, 43, 51].  We sought to attenuate the reduced 
endothelial response to postprandial hyperglycemia via supplementation with WMJ which has 
shown to have promising endothelial effects.   
4.2 Oral Glucose Tolerance Test  
A 75-gram glucose OGTT was administered to induce a hyperglycemic response which 
has been shown to increase plasma glucose levels rapidly causing vascular resistance despite the 
following increase in plasma insulin.  Glucose was elevated as expected and peak glucose 
occurred at the 30-minute time and stayed elevated at 60 minutes in accordance with similar 
trials in healthy individuals [8,43].  WMJ groups showed no significant differences in 
hyperglycemia indicating changes in FMD or NIRS were not derived from differences in plasma 
glucose. 
4.3 Flow-Mediated Dilation 
We expected to see decrements in FMD% when plasma glucose was at peak indicating 
the attenuated endothelial response caused by hyperglycemia in response to an OGTT as shown 
by Russell et al [51].  The change in vessel diameter (FMD%) was assessed at 60 seconds, 180 
seconds, and 300 seconds after cuff release. Peak vessel diameter change was reduced 30-
minutes post glucose ingestion.  Mah et al. reported a similar decrement in FMD but at 60 
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minutes post glucose ingestion, this could be due to our population including healthy females 
and males as opposed to solely males [18].  Black et al (2005) reported 58% of peak FMD% 
were found from 50-70 seconds post cuff release in healthy young individuals [52].  Conversely, 
80% of our participants reached peak FMD% at 60 seconds at baseline, but 30 minutes following 
glucose ingestion the time to peak FMD% increased then recovers similar to baseline.  This is 
likely attributed to the peak in glucose occurring at the same time followed by the vasodilatory 
response of insulin in the later time points.  This interaction could also be linked to peak glucose, 
further attenuating vasoresponsiveness during hyperglycemia.  Baseline FMD% significantly 
increased with the supplementation of WMJ when compared to PLA.  This response can likely 
be attributed to the prolonged supplementation of citrulline leading to increased NO 
bioavailability.  In conjunction with FMD, the NIRS data also exhibited similar promising 
trends.   
4.4 Near-Infrared Spectroscopy 
Following the trends with FMD, we observed a decrease in baseline StO2 at 30 minutes 
in both groups where peak glucose occurred.  In the WMJ group, there was a trend toward a 
significant treatment effect (p=0.11) as well as a significant time effect (p=0.03) when compared 
to the placebo.  The observed improvement in baseline StO2 suggests WMJ attenuates the 
reduction of endothelial function observed during hyperglycemia.  Supplementing with WMJ 
significantly increased baseline StO2 AUC which is likely related to improved chronic 
endothelium function.  Soares et al. (2017) noted a linear significant increase in slope 2 
(reperfusion slope) at 90 minutes post glucose ingestion, however, they did not measure insulin 
which is a major vasodilator [43].  In our hands, we noted a similar trend in PLA peak slope 2 at 
60 minutes, whereas the WMJ group demonstrated peak slope 2 at 30 minutes post glucose 
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ingestion, despite having a significant time effect (p=0.043).  McLay et al (2016) suggest that 
slope 2 is a more repeatable measure of vascular responsiveness than FMD% [53].  We observed 
a significant inverse relationship (p=0.0002) in glucose and slope 2 displaying that 
hyperglycemia impairs skeletal muscle reperfusion. There was no correlation between 
reperfusion AUC (8-minute) and slope 2 whereas Soars et al (2017) reported an inverse 
relationship between the two [43].  We did not detect a significant treatment effect for the 
reperfusion AUC (8-minute) despite a trend toward improvement with WMJ (p=0.13).  
Likewise, the mean reperfusion AUC (8-minute) was also nearly significant (p=0.08). It is 
reasonable to speculate that WMJ supplementation improves the vascular environment during 
hyperglycemia based on the sustain higher StO2 and trend towards improved vascular 
reperfusion.  In T2D as well as hyperglycemia microvascular blood flow is significantly reduced 
[9,10,18,51].  We observed a significant time effect (p=0.023) in microvasculature blood flow 
with a reduction in blood flow at peak glucose.  Baseline microvasculature blood flow trends 
towards significance in the WMJ group 
4.5 Limitations 
 This study was designed to investigate upstream and downstream vascular responsiveness 
to 2 weeks of WMJ supplementation shown to provide an additional 3g of Citrulline compared to 
supplementation with a placebo designed to taste similar to the WMJ.  Technical limitations 
prevented the assessment of simultaneous pulse wave velocity with a high-quality B mode video.  
Instead, we used NIRS to measure microvascular blood flow.  Cardiovascular fitness is a major 
predictor of endothelial function and vascular health.  We did require a physical activity 
questionnaire and asked participants to abstain from exercise prior to study visits, general 
physical activity was not accounted for.  Last, we cannot confirm the pancreatic responsiveness 
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to the OGTT with insulin or determine the effectiveness of the WMJ supplementation to raise L-
citrulline levels.  However, in the future, we will use archival samples from this study to measure 
serum insulin and L-citrulline levels.  At the present time, we do not have serum insulin or 
circulation markers of NO activity (Nitrate) these analyses will be run in the future.   
4.6 Considerations for Future Research 
 Future research could investigate at a combination supplement of citrulline, arginine, and 
nitrates in conjunction to possibly elicit a more robust response.  The data from this study give 
merit for a similar study in individuals with decreased vascular responsiveness such as T2D or 
family history of T2D.  
4.7 Conclusion 
 The main finding of this study confirms the previously reported relationship between 
hyperglycemia and decreased skeletal muscle microvascular function. We also confirmed 
decreased endothelial function, in a healthy-young population, during an OGTT. The purpose of 
this study was to determine the effect of WMJ supplementation on endothelial function and 
skeletal muscle microvascular function during experimental hyperglycemia.  We demonstrated 
WMJ supplementation is an effective method for improving vascular responsiveness during 
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